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Abstract
Background Nicotine, the pharmacologically active substance in both tobacco and many electronic cigarette (e-cigarette) 
liquids, is responsible for the addiction that sustains cigarette smoking. With 8 million deaths worldwide annually, smoking 
remains one of the major causes of disability and premature death. However, nicotine also plays an important role in smok-
ing cessation strategies.
Objectives The aim of this study was to develop a comprehensive, whole-body, physiologically based pharmacokinetic/
pharmacodynamic (PBPK/PD) model of nicotine and its major metabolite cotinine, covering various routes of nicotine 
administration, and to simulate nicotine brain tissue concentrations after the use of combustible cigarettes, e-cigarettes, 
nicotine gums, and nicotine patches.
Methods A parent–metabolite, PBPK/PD model of nicotine for a non-smoking and a smoking population was devel-
oped using 91 plasma and brain tissue concentration–time profiles and 11 heart rate profiles. Among others, cytochrome 
P450 (CYP) 2A6 and 2B6 enzymes were implemented, including kinetics for CYP2A6 poor metabolizers.
Results The model is able to precisely describe and predict both nicotine plasma and brain tissue concentrations, cotinine 
plasma concentrations, and heart rate profiles. 100% of the predicted area under the concentration–time curve (AUC) and 
maximum concentration (Cmax) values meet the twofold acceptance criterion with overall geometric mean fold errors of 1.12 
and 1.15, respectively. The administration of combustible cigarettes, e-cigarettes, nicotine patches, and nicotine gums was 
successfully implemented in the model and used to identify differences in steady-state nicotine brain tissue concentration 
patterns.
Conclusions Our PBPK/PD model may be helpful in further investigations of nicotine dependence and smoking cessation 
strategies. As the model represents the first nicotine PBPK/PD model predicting nicotine concentration and heart rate profiles 
after the use of e-cigarettes, it could also contribute to a better understanding of the recent increase in youth e-cigarette use.
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Key Points 
A whole-body, parent–metabolite, physiologically based 
pharmacokinetic/pharmacodynamic model of nicotine 
was built and evaluated for the prediction of nicotine 
and cotinine plasma concentrations, nicotine brain tis-
sue concentrations, and heart rate profiles after nicotine 
intake. The model was able to quantify the contribution 
of the elimination pathways of nicotine being metabo-
lized to cotinine and renally excreted.
The model was applied to simulate nicotine brain tissue 
concentration patterns after smoking cigarettes, the 
administration of nicotine gums (2 mg and 4 mg), and a 
transdermal nicotine patch.
This study demonstrates the applicability of physiologi-
cally based pharmacokinetic modeling to investigate 
brain tissue concentrations and to successfully integrate 
many different routes of administration in one model: 
intravenous, pulmonary (combustible cigarettes and elec-
tronic cigarettes), oral (solutions, capsules, and nicotine 
gums), and transdermal (nicotine patches). Moreover, 
it represents the first nicotine physiologically based 
pharmacokinetic model that predicts nicotine plasma 
concentration and heart rate profiles after the use of 
electronic cigarettes.
1 Introduction
Tobacco use is now the leading single preventable cause of 
death worldwide, causing 8 million deaths per year mainly 
from cardiovascular disease, cancer, and pulmonary disease, 
according to the latest World Health Organization (WHO) 
report on the global tobacco epidemic in 2019 [1]. Moreover, 
despite more than 70% of smokers wanting to quit and 40% 
attempting to do so each year, only about 5% are successful 
[2]. The highly addictive nature of tobacco is caused mainly 
by the pharmacologically active nicotine and often impedes 
smoking withdrawal [3]. The low quit rates highlight the 
tremendous need for more successful smoking cessation 
strategies. In addition, health risks of electronic cigarettes 
(e-cigarettes) are currently a topic of considerable debate. 
Preliminary data from the US National Youth Tobacco Sur-
vey indicate a further rise in the rates of e-cigarettes use by 
youth, where the addictive properties of nicotine also play an 
important role, and which was recently called an “epidemic 
of youth use of electronic nicotine delivery system prod-
ucts” by the US Food and Drug Administration [4]. While 
e-cigarettes assist smoking cessation for some smokers, the 
escalating rates raise concerns about addicting a generation 
of young people to nicotine, with the long-term safety of 
e-cigarettes still unknown [5]. A better understanding of dif-
ferences in the pharmacokinetics (PK) of nicotine, includ-
ing nicotine exposure in the brain after different routes of 
administration, may enhance the understanding of nicotine 
addiction with the use of different nicotine delivery products 
and inform more successful treatment interventions.
While nicotine plays only a minor direct role in causing 
smoking-induced diseases, addiction to nicotine is the proxi-
mate cause of these diseases [3]. When nicotine is inhaled, 
it is rapidly absorbed into the pulmonary venous circulation, 
and quickly reaches the brain tissue through arterial circula-
tion. There, it immediately induces pharmacodynamic (PD) 
effects including the release of dopamine in the mesolim-
bic area, a key step in causing nicotine addiction [6]. For 
smokers who intend to quit smoking, nicotine maintenance 
with nicotine replacement therapies (NRTs) such as nicotine 
gums or transdermal patches can help reduce smoking rates 
and facilitate smoking cessation [7, 8]. Although NRTs try 
to imitate the nicotine exposure of smoking, nicotine appear-
ance in the venous blood is slower and peak concentrations 
are lower with the use of NRTs, compared with smoking 
combustible cigarettes [9, 10]. Data on nicotine brain tissue 
concentrations are scarce and typically complex in nature 
[11]. Nevertheless, it would be of great interest to also com-
pare differences in nicotine exposure in brain tissue after 
various routes of nicotine administration.
Genetic factors account for about 30% of the variance 
in risk for failed smoking cessation [12] and pharmacoge-
netic testing has shown the potential to optimize smoking 
cessation therapies [13, 14]. Thus, cytochrome P450 (CYP) 
enzymes, which are involved in metabolizing nicotine, are of 
significant interest when investigating nicotine pharmacoki-
netics. For example, poor metabolizers (PM) of CYP2A6, 
which is predominantly responsible for nicotine metabolism 
[15], have a lower risk of developing nicotine dependence 
and less severe nicotine withdrawal symptoms than normal 
metabolizers (NM) [16].
In addition to its addictive effects on the brain, nicotine 
acts as a sympathomimetic drug, releasing catecholamines 
and thereby inducing peripheral PD effects such as an 
increase in heart rate [17]. Changes in heart rate represent 
a surrogate measure for general pharmacological actions 
of nicotine. Cotinine is widely used as a biomarker for the 
use of tobacco, as a quantitative marker for exposures to 
nicotine, and as a measure of compliance with treatments of 
smoking cessation, owing to its long half-life compared with 
nicotine (~ 16 h vs ~ 2 h) and consequently, fairly stable coti-
nine plasma concentrations in regular daily smokers [6, 18].
Physiologically based pharmacokinetic (PBPK) modeling 
offers a solution to tackle these complexities of nicotine 
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pharmacokinetics and pharmacodynamics and provides the 
opportunity to characterize and predict drug exposure in a 
specific organ or tissue [19]. The aims of this study were (1) 
to develop a whole-body PBPK/PD model of nicotine and its 
major metabolite cotinine, covering various routes of admin-
istration (i.e., intravenous, oral, transdermal, and pulmonary) 
including the PK/PD relationship in heart rate changes, (2) 
to provide a comprehensive publicly available model for fur-
ther investigations and applications, which may contribute 
to the WHO’s goal of combating the tobacco epidemic and 
to stop the persistent rise in youth e-cigarette use [1, 4], and 
finally, (3) to apply the model to investigate differences in 
brain concentrations between pulmonary administration of 
nicotine (combustible cigarettes, e-cigarettes) and NRTs.
2  Methods
2.1  Software
The PBPK/PD modeling and simulation was performed 
using PK-Sim® and  MoBi® (version 8.0, part of the Open 
Systems Pharmacology [OSP] suite, https ://www.open-syste 
ms-pharm acolo gy.org). Model input parameter optimization 
was accomplished using the Monte Carlo algorithm. Clinical 
data were digitized using GetData Graph Digitizer version 
2.26.0.20 (S. Fedorov). PK parameter analyses and graph-
ics were compiled with the R programming language ver-
sion 3.6.0 (R Foundation for Statistical Computing, Vienna, 
Austria).
2.2  Physiologically Based Pharmacokinetic/
Pharmacodynamic (PBPK/PD) Parent–
Metabolite Model Building
For PBPK/PD model building, an extensive literature search 
was performed to collect information on physicochemical 
properties, liberation, absorption, distribution, metabolism, 
and excretion (LADME) processes and clinical studies of 
intravenous, oral, pulmonary, and transdermal administra-
tion of nicotine and intravenous administration of cotinine 
in single- and multiple-dose regimens. Plasma concentra-
tion–time profiles, a brain tissue concentration–time profile, 
fractions of nicotine and cotinine doses excreted unchanged 
to urine, and heart rate profiles were digitized from 34 
clinical studies with 75 different treatment blocks and 891 
patients and split into an internal training (n = 26 profiles) 
and an external test (n = 76 profiles) dataset (for detailed 
information on clinical studies, see Tables S2.6.1–S2.6.3 of 
the Electronic Supplementary Material [ESM]). The internal 
training dataset was used for model building and together 
with the external test dataset, for model evaluation. The 
training dataset was selected so as to inform all physiological 
processes implemented in the model (e.g., contribution of 
the CYP2B6 elimination pathway, estimation of urinary 
excretion).
Hence, for cotinine PBPK model building, three plasma 
profiles of cotinine administered intravenously were used, 
which covered a broad dosing range and included informa-
tion on urinary excretion of cotinine. For the nicotine PBPK 
model building, plasma profiles of non-smokers and smokers 
after intravenous administration were included in the train-
ing dataset, with a broad dosing range, including studies 
with cotinine metabolite data, information on the fraction 
of nicotine excreted unchanged to urine, and the fraction 
of nicotine metabolized to cotinine. Moreover, a study with 
plasma concentrations of CYP2A6 poor metabolizers and a 
study with brain tissue concentrations after nicotine intake 
were included in the training dataset, to inform model input 
parameters for CYP2B6 and brain transporters. For the PD 
heart rate model, three studies with intravenous administra-
tion were used for model training, which covered the larg-
est timeframe of heart rate measurements and the highest 
nicotine peak plasma concentrations. Values for model input 
parameters that could not be adequately obtained from the 
literature were estimated by fitting first the cotinine model 
and subsequently the nicotine model to the training dataset.
The parent–metabolite PBPK/PD model was derived 
using a stepwise approach. Initially, a cotinine model was 
developed based on cotinine intravenous training data from 
healthy non-smoking volunteers. Second, the cotinine model 
was complemented by a comprehensive PBPK model of the 
parent compound nicotine, including intravenous, oral, and 
pulmonary administration of nicotine, using the internal 
dataset for model training. Third, the oral route of admin-
istration for nicotine gums and a transdermal model were 
established and added to the parent–metabolite PBPK 
model. Fourth, a modified heart rate-tolerance PD model 
based on a recently published tolerance model, including 
circadian rhythm [20] was incorporated into the PBPK 
model to describe the positive chronotropic effect of nico-
tine. Finally, the resulting PBPK/PD model was evaluated 
and used to simulate brain tissue concentration patterns after 
nicotine administration through different routes.
Distribution and elimination processes including CYP 
enzymes and transporters were implemented according to 
the literature [15, 21–23]. For the nicotine model, these are 
(1) metabolism of nicotine to its major metabolite cotinine 
through CYP2A6 and CYP2B6, (2) an unspecific hepatic 
clearance being responsible for the remaining hepatic 
metabolism of nicotine including metabolism via uridine 
5ʹ-diphospho-glucuronosyltransferase 2B10 (UGT2B10) 
and flavin-containing monooxygenase 3 (FMO3), and (3) 
two transporters for the influx and efflux of nicotine across 
the blood–brain barrier (BBB). For cotinine, an unspecific 
hepatic clearance was implemented. Additionally, renal 
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excretion through glomerular filtration was implemented as 
an elimination pathway for both compounds, as they are sub-
ject to glomerular filtration under physiological conditions 
[15, 24]. Reported differences in nicotine clearance between 
smokers and non-smokers [25] were addressed by estimating 
different values for the CYP2A6 catalytic rate constant (kcat).
A PD model was added to the PBPK model to describe 
the positive chronotropic effect of nicotine [9, 26] based 
on its PK. The model, which best described the heart rate 
including the drug effect, was a direct-effect Emax model with 
absolute effect, including a tolerance development based on 
a recently published heart rate tolerance model [20]. Fig-
ure 1 shows a structural overview of the developed PBPK/
PD model. The tolerance compartment was implemented to 
describe the extent of acute tolerance development of the 
system and its subsequent reduction in the drug effect on 
heart rate following the administration of nicotine [27]. The 
appearance of tolerance was set to depend on the concentra-
tion of nicotine, which has been shown in the literature [27]. 
For detailed information on PBPK/PD model building and 
virtual populations, see Sect. 2 of the ESM.
2.3  PBPK Model of Nicotine Patches, Nicotine 
Gums, Combustible Cigarettes, and Electronic 
Cigarettes
To model and simulate the transdermal application of nico-
tine with nicotine patches, a transdermal two-compartment 
skin model was implemented with  MoBi® and added 
to the default PBPK model. To model and simulate the 
administration of nicotine gums, an oral formulation was 
used. The corresponding nicotine release was implemented 
according to a published in vitro release profile of  Nicorette® 
chewing gums [28]. A pulmonary route of administra-
tion was applied within PK-Sim® to model and simulate 
the inhalation of nicotine with combustible cigarettes and 
e-cigarettes. Zero-order kinetics were chosen for pulmonary 
formulations with a duration of the length of smoking, which 
is supported by the literature [29]. For detailed information 
see Sects. 2.2–2.4 of the ESM.
2.4  PBPK/PD Model Evaluation
All the 102 nicotine and cotinine concentration–time profiles 
and heart rate profiles observed of the training and test data-
sets were compared to predicted profiles. Virtual populations 
of 100 individuals for each study were established according 
to the population demographics of the respective simulated 
study. Population predictions were plotted as geometric 
mean with geometric standard deviation. Visual descriptive 
(training dataset) and predictive (test dataset) performances 
of the PBPK/PD model are shown in Sect. 3 and in detail in 
Sects. 3.1–3.6 and 3.11 of the ESM. Model performance was 
also evaluated by comparing predicted plasma concentra-
tions with their respective values observed in goodness-of-
fit plots. Additionally, the predicted vs observed area under 
the concentration–time curve from the first to the last data 
point (AUC last) and maximum concentration (Cmax) values 
were compared in goodness-of-fit plots. The sensitivity of 
the final PBPK model to single parameter changes (local 
Fig. 1  Structural overview 
of the developed physiologi-
cally based pharmacokinetic/
pharmacodynamic (PBPK/PD) 
model for the intravenous, oral, 
transdermal, and pulmonary 
administration of nicotine. 
Boxes indicate compartments, 
solid lines denote in-/out-flows, 
dashed lines indicate relation-
ships. GIT gastrointestinal tract, 
TTS transdermal therapeutic 
system
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sensitivity analysis) was investigated with PK-Sim®. Further, 
two quantitative performance measures were calculated: the 
mean relative deviation (MRD) of the predicted plasma con-
centrations for each plasma profile and the geometric mean 
fold errors (GMFE) of AUC last and Cmax, respectively (see 
Sects. 3.8–3.10 of the ESM).
3  Results
3.1  PBPK Model Building and Evaluation
The whole-body PBPK model of nicotine and cotinine pre-
cisely describes and predicts plasma concentration–time 
profiles following intravenous, oral, transdermal, and pul-
monary administration and data on brain tissue concentra-
tions (see Figs. 2, 3, 4, 5). For the building and evaluation 
of the nicotine parent–metabolite PBPK model, 90 plasma 
concentration–time profiles including 18 cotinine metabo-
lite profiles, a brain tissue concentration–time profile, six 
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Fig. 2  Predicted vs observed nicotine and cotinine area under the 
concentration–time curve from the first to the last data point (AUC) 
[a, b] and maximum concentration (Cmax) [c, d] values of the inter-
nal training and the external test dataset. Each symbol represents the 
AUC or Cmax of a single concentration–time profile (circles: nicotine, 
triangles: cotinine metabolite and cotinine intravenous [iv]). The 
black solid lines mark the lines of identity. Black dotted lines indicate 
a 1.25-fold deviation, black dashed lines indicate a twofold deviation. 
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studies on the fraction of nicotine and cotinine excreted 
unchanged to urine, and one study depicting the fraction of 
nicotine metabolized to cotinine were used. Drug-dependent 
parameters of the final parent–metabolite PBPK model are 
depicted in Table 1. A study overview including key metrics 
and a detailed description of the PBPK model are listed in 
Sect. 2 of the ESM.
The good descriptive and predictive model performance 
is comprehensively demonstrated. Visual comparisons of 
predicted to observed plasma concentration–time profiles 
are depicted in Figs. 3, 4, 5 (selection of internal and exter-
nal datasets for each route of administration) and in detail in 
Sects. 3.1–3.6 of the ESM (all studies, linear and semiloga-
rithmic plots). The predictions of plasma concentration–time 
trajectories for all routes of administration are in close agree-
ment with observed plasma concentration data. Moreover, 
goodness-of-fit plots of predicted to observed AUC last and 
Cmax are shown in Fig. 2 and for each route of administration 
separately in Sects. 3.1–3.6 of the ESM together with good-
ness-of-fit plots of observed vs predicted plasma concen-
trations. In summary, 100% of both the predicted AUC last 
and Cmax values appear to be within the twofold acceptance 
criterion. The GMFE values for the nicotine PBPK model 
are 1.11 and 1.17 for AUC last and Cmax, respectively, and 
1.14 and 1.11 for the cotinine model. Overall MRD for the 
nicotine and cotinine PBPK model are 1.44 and 1.77, respec-
tively. Detailed results on GMFE and MRD values calcu-
lated for all studies are given in Sect. 3.8 of the ESM and 
the results of the sensitivity analysis are shown in Sect. 3.10 
of the ESM.
Nicotine is mainly metabolized through CYP2A6. How-
ever, in CYP2A6 PMs, when people lack CYP2A6 metabo-
lism and cotinine production diminishes (CYP2A6-kcat of 
0), CYP2B6 is responsible for a modest nicotine conver-
sion to cotinine [15, 22]. A CYP2A6 PM plasma concen-
tration–time profile was included in the training dataset to 
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Fig. 3  Nicotine predicted and observed plasma (blue) and brain tissue 
(gold) concentration–time profiles after administration of combustible 
cigarettes (with estimated pulmonary nicotine exposure for plasma 
simulations) and electronic cigarettes (e-cig.). Population simula-
tion (n = 100) geometric means are shown as lines; the shaded areas 
represent the predicted population geometric standard deviations 
(SDs). Observed data are shown as filled circles ± SD. (i): selection of 
internal training dataset, (e): selection of external test dataset. Refer-
ences with numbers in parentheses link to a specific observed data-
set described in the study table with detailed information about dos-
ing regimens (Tables S2.6.1 and S2.8.2 of the ESM). Predicted and 
observed area under the concentration–time curve (AUC) and maxi-
mum concentration (Cmax) values are compared in Table S3.8.2 of the 
ESM. comb. cig. combustible cigarette, iv intravenous [9, 11, 70–73]
1125PBPK/PD Model of Nicotine Including Brain Concentration Patterns during Smoking and Smoking Cessation Strategies
estimate CYP2B6 metabolism in the model and to describe 
nicotine plasma concentrations in CYP2A6 PMs (see 
Fig. 5d) [40]. Additionally, nicotine clearance in smokers 
appears to be about 15% lower, compared with non-smokers 
[25]. To account for this difference, CYP2A6-kcat was esti-
mated separately for the smoker subpopulation, leading to 
a lower kcat in comparison to the non-smoker subpopula-
tion (see Table 1). For detailed information including drug-, 
system-, and formulation-dependent model parameters, see 
Sect. 2.1 of the ESM and Tables S2.7.1, S2.8.1–2.8.3, and 
S2.10.1 of the ESM.
The resulting PBPK model predicts a fraction of nicotine 
metabolized to cotinine of about 75%, which perfectly aligns 
with literature reports (70–80%) [15, 22, 23]. Moreover, pre-
dicted bioavailabilities after oral (~ 35%) and pulmonary 
(~ 85%) administration of nicotine are in concordance with 
the literature (20–45% and 80–90%, respectively) [9, 15, 46].
As the published literature suggests, the influx and efflux 
of nicotine over the BBB play an important role in the char-
acteristics of nicotine brain tissue concentrations [21]. As 
a result, an influx and an efflux transporter with Michae-
lis–Menten kinetics were implemented in the BBB, which 
led to a precise description of experimental nicotine brain 
tissue concentrations after a puff of a combustible cigarette 
(see Fig. 3e) [11].
It is known that machine smoking yields of combus-
tible cigarettes are not equivalent to human measures of 
nicotine uptake [47, 48]. Hence, when machine smoking 
yields are used as nicotine doses for simulation of plasma 
concentrations, the model underpredicts observed data for 
low machine smoking yields and overpredicts observed 
data for high machine smoking yields (see Fig. S3.6.1 
of the ESM). Therefore, pulmonary nicotine exposure 
for combustible cigarettes was estimated additionally 
as described in Sect. 2.4 of the ESM (mean deviation to 
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Fig. 4  Nicotine (blue) and cotinine (purple if administered intrave-
nously, green if metabolite) predicted and observed plasma concen-
tration–time profiles after intravenous administration. a–c Non-smok-
ers, d–f: smokers. Population simulation (n = 100) geometric means 
are shown as lines; the shaded areas represent the predicted popula-
tion geometric standard deviations (SDs). Observed data are shown 
as filled circles, if available ± SD. (i): selection of internal training 
dataset, (e): selection of external test dataset. References with num-
bers in parentheses link to a specific observed dataset described in the 
study table with detailed information about dosing regimens (Tables 
S2.6.1 and S2.6.2 of the ESM). Predicted and observed area under the 
plasma concentration–time curve (AUC) and maximum plasma con-
centration (Cmax) values are compared in Table S3.8.2. of the ESM. iv 
intravenous [22, 27, 74–76]
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machine smoked nicotine yields of 31%), leading to the 
precise predictions of plasma profiles observed (see Fig. 3 
and Fig. S3.5.1 of the ESM).
For the administration of nicotine through transdermal 
therapeutic systems (TTS), the default PK-Sim® PBPK 
model was expanded with a two-compartment skin model, 
which consists of the lipophilic stratum corneum and the 
hydrophilic deeper skin layer routes. The resulting model 
successfully describes and predicts plasma profiles after 
single and multiple doses of nicotine patches (see Fig. 5e, 
f and Sect. 3.4 of the ESM). The model was also able to 
predict nicotine plasma profiles during the use of nicotine 
gums in single- and multiple-dose studies (see Fig. 5a, b 
and Sect. 3.3 of the ESM) and cotinine steady-state plasma 
concentrations observed in several studies (see Fig. 5c, f 
and Sect. 3.3 of the ESM) [18].
3.2  Brain Concentrations after Different Routes 
of Administration
The model was used to simulate steady-state brain tissue 
concentrations throughout a day when smoking combus-
tible cigarettes or e-cigarettes (16 cigarettes during 16 h), 
administering nicotine gums (16 gums during 16 h), or 
applying a nicotine patch (for 24  h). Simulations and 
results of the comparison of area under the brain tissue 
concentration–time curves, maximum brain tissue con-
centrations, and peak-trough differences for each type of 
nicotine administration are depicted in Fig. 6.
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Fig. 5  Nicotine (blue) and cotinine metabolite (green) predicted and 
observed plasma concentration–time profiles after oral (gum, solu-
tion, capsule) and transdermal administration. Population simulation 
(n = 100) geometric means are shown as lines; the shaded areas rep-
resent the predicted population geometric standard deviations (SDs). 
Observed data are shown as circles, if available ± SD. (i): selection of 
internal training dataset, (e): selection of external test dataset. Refer-
ences with numbers in parentheses link to a specific observed data-
set described in the study table with detailed information about dos-
ing regimens (Tables S2.6.1 and S2.8.3 of the ESM). Predicted and 
observed area under the plasma concentration–time curve (AUC) 
and maximum plasma concentration (Cmax) values are compared in 
Table  S3.8.2. of the ESM. caps capsule, NM normal metabolizer, 
patch transdermal therapeutic system (nicotine patch), PM poor 
metabolizer, po oral, q.i.d. four times daily [18, 40, 62, 77–79]
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Table 1  Drug-dependent and pharmacodynamic (PD) parameters of the final parent–metabolite physiologically based pharmacokinetic/pharma-
codynamic (PBPK/PD) model
Parameter Unit Nicotine model Cotinine model Descriptiona
Value used in simu-
lation
Literature value 
[Ref]
Value used in simu-
lation
Literature value 
[Ref]
PBPK model
 MW g/mol 162.2 162.2 [30]b 176.2 176.2 [30]c Molecular weight
 pKa1 8.1 (basic) 8.1 [31] 4.5 (basic) 4.5 [32] Acid dissociation 
constant 1
 pKa2 3.3 (basic) 3.3 [31] Acid dissociation 
constant 2
 logP 1.6 1.2, 1.4 [31, 33] − 0.1f 0.21 [30]c Lipophilicity
 Solubility (pH) mg/mL 93.3 (7.0) 93.3 (7.0) [30]b 117.0 (7.0) 117.0 (7.0) [30]c Solubility
 fu % 95.1 80.0–95.1 [34] 97.4 97.4 [35] Fraction unbound 
(plasma)
 CYP2A6 KM µmol/L 29.4f 11.0, 32.0, 33.0, 
144.0 [36–39]
CYP2A6 Michaelis–
Menten constant
 CYP2A6-NM kcat 
(non-smokers)
1/min 12.0f – CYP2A6-NM cata-
lytic rate constant 
for non-smokers
 CYP2A6-NM kcat 
(smokers)
1/min 10.5f – CYP2A6-NM cata-
lytic rate constant 
for smokers
 CYP2A6-PM kcat 1/min 0.0 0 [40] CYP2A6-PM catalytic 
rate constant
 CYP2B6 KM μmol/L 820.0 820.0 [41] CYP2B6 Michaelis–
Menten constant
 CYP2B6 kcat 1/min 16.0f – CYP2B6 catalytic rate 
constant
 BBB-transporterin 
KM
μmol/L 92.4 92.4 [21] BBB  transporterin 
Michaelis–Menten 
constant
 BBB-transporterin 
kcat
1/s 5.3E + 03f – BBB-transporterin 
catalytic rate con-
stant
 BBB-transporterout 
KM
μmol/L 7.0E − 05f – BBB-transporterout 
Michaelis–Menten 
constant
 BBB-transporterout 
kcat
1/s 0.4f – BBB-transporterout 
catalytic rate con-
stant
 GFR fraction 1.0 – 6.0E − 02f – Fraction of GFR used 
for passive elimina-
tion by the kidney
 Unspecific hepatic 
clearance
1/min 0.3f – 2.0E − 02f – Elimination from 
plasma (first-order 
process in the liver)
 Calculation 
method of parti-
tion coefficients
Rodgers and Row-
land [42–44]
PK-Sim® standard 
[45]d
Organ-plasma parti-
tion coefficients
 Calculation 
method of cell 
permeabilities
PK-Sim® standard 
[45]d
PK-Sim® standard 
[45]d
Permeation across cell 
membranes
PD  modele
 Emax bpm 111.6f – Maximum possible 
heart rate elevation 
without tolerance
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3.3  PBPK/PD Model Building and Evaluation
The PBPK model has been augmented with a PD nicotine 
heart rate model (see Fig. 1). The integrated PBPK/PD 
model is able to capture the effect of nicotine that leads to 
heart rate peaks rapidly after intravenous and pulmonary 
nicotine intake. A total of 11 studies evaluating the effect 
of nicotine on heart rate were used for PD model building 
and evaluation. Study details and key metrics are listed in 
Table S2.6.3 of the ESM. Parameters of the final PBPK/PD 
model are listed in Table 1. PD model performance for both 
the internal training and the external test dataset is demon-
strated by comparing the population predicted to heart rate 
profiles observed in Fig. 7 (representative studies) and in 
detail in Sect. 3.11 of the ESM (all studies).
4  Discussion
The main outcome of this study is the development of a 
comprehensive parent–metabolite PBPK/PD model of a 
drug, which is consumed by over 1.1 billion smokers and 
which is also used in NRTs as an important smoking cessa-
tion strategy [1]. The model provides a consistent represen-
tation of the nicotine dose-exposure relationship following 
intravenous, oral, transdermal, and pulmonary administra-
tion in non-smoking and smoking populations. It precisely 
describes and predicts nicotine and cotinine plasma and nic-
otine brain tissue concentrations. Thereby, the model is able 
to quantify the contribution of the elimination pathways of 
the fraction of nicotine metabolized to cotinine and urinary 
excretion of both nicotine and cotinine. Further, the PBPK 
model has been expanded by a heart rate tolerance model, 
which includes circadian rhythm, describing the positive 
chronotropic effect of nicotine. Finally, the model was used 
to identify differences in brain concentrations between pul-
monary administration of nicotine (combustible cigarettes, 
e-cigarettes) and NRTs.
To reduce smoking dependence, exposure to smoke toxi-
cants, and youth e-cigarette use, all of which are critical pub-
lic health goals [1, 4], it is crucial to have quantitative tools 
to better understand both smoking behavior and dependence 
on nicotine. This model represents an opportunity to simu-
late concentrations of nicotine in blood plasma and brain 
tissue with requested dosing regimens after four different 
routes of administration.
Five other PBPK models of nicotine have been developed 
so far; however, either important routes of administration, a 
PD heart rate model, comprehensive predictive performance, 
and/or the inclusion of a large number of clinical studies are 
missing [49–53]. The models developed by Plowchalk et al. 
(for rats), Robinson et al., and Yamazaki et al. (for humans) 
presented simplified implementations of the nicotine ADME 
processes [49–51]. While Teeguarden et al. stated that their 
BBB blood–brain barrier, bpm beats/min, CYP cytochrome P450, GFR glomerular filtration rate, kcat catalytic rate constant, NM normal metabo-
lizer, PM poor metabolizer, Ref reference, - not available
a Descriptions for PD parameters carried over from [20]
b DrugBank entry for nicotine. Available from: https ://www.drugb ank.ca/drugs /DB001 84 [Accessed 21 Oct 2019]
c DrugBank entry for cotinine. Available from: https ://www.drugb ank.ca/metab olite s/DBMET 00519 . [Accessed 21 Oct 2019]
d Equations and descriptions of calculations can be found in [45]
e Individual heart rate baselines and circadian time shift for different study populations are depicted in Sect. 2.9 of the ESM
f Model input parameter estimated
Table 1  (continued)
Parameter Unit Nicotine model Cotinine model Descriptiona
Value used in simu-
lation
Literature value 
[Ref]
Value used in simu-
lation
Literature value 
[Ref]
 EC50 μmol/L 0.21f – Concentration at half-
maximum elevation
 h 1.3f – Hill coefficient
 tolin 1/h 15.3f – Tolerance appearance 
rate
 tolout 1/h 0.2f – Tolerance disappear-
ance rate
 tol50 μmol/L 0.07f – Scaling parameter for 
tolerance
 amp % 6.3 6.3 [20] Circadian amplitude
 γ 0.4f – Non-linearity param-
eter
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“results should not at this time be considered accurate pre-
dictions of outcomes in a population of smokers”, they pre-
sented one of the first broad models including several routes 
of nicotine administration (without a transdermal route) 
and a PD model [52]. The most current nicotine PBPK/PD 
model, by Gajewska et al., accurately described heart rate 
changes after transdermal nicotine intake but struggled to 
predict heart rate peaks occurring after intravenous nico-
tine administration and nicotine plasma concentrations after 
the removal of nicotine patches [53]. While the previously 
mentioned models provide the information in a condensed 
form to investigate the models independent of the underly-
ing platform, the presented model relies on the application 
within the OSP framework. However, all the information can 
be accessed through the model file, which is publicly avail-
able in the OSP repository for application and investigation 
purposes.
Our PBPK/PD model incorporates comprehensiveness 
of both the routes of administration (intravenous, trans-
dermal [patches], oral [including gums], and pulmonary 
[combustible cigarettes and e-cigarettes]) and the number 
of plasma, brain tissue, and heart rate profiles included 
(n = 102) to develop the model. Moreover, this study pre-
sents a novel opportunity to simulate nicotine brain tissue 
concentrations after different routes of administration, 
based on incorporated information on brain tissue con-
centrations, in PK-Sim® and  MoBi®.
In contrast with already published nicotine PBPK 
models, this study includes the two most important CYP 
enzymes for nicotine metabolism, CYP2A6 and CYP2B6, 
both highly polymorphic, and incorporated differences 
between CYP2A6 PMs and NMs [15, 40, 54]. This is 
crucial for the individualization of NRTs to avoid poor 
response and adverse drug reactions [55, 56], as phar-
macogenetic testing has shown the potential to optimize 
smoking cessation therapies [13, 14]. Because only one 
plasma–concentration time profile for PMs was available 
and concentrations were determined only over 6 h, simula-
tions of plasma concentrations may be less accurate over 
longer time periods. Hence, additional research on the PK 
of PMs would be of great interest. The enzymatic path-
ways responsible for nicotine glucuronidation (UGT2B10) 
and N-oxidation (FMO3) are subsumed under the unspe-
cific hepatic clearance process.
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Fig. 6  Simulations of brain tissue concentration–time profiles after 
pulmonary (16 h), oral (2 mg and 4 mg gums, 16 h), and transdermal 
(patch, 24 h) administration (a–d) and analysis of the area under the 
brain tissue concentration–time curve (AUC) of nicotine brain tissue 
concentrations for the first 16 h (gray) and the last 8 h (orange) (e), 
maximum brain tissue concentrations (Cmax) (f), and peak-trough dif-
ferences in brain tissue concentrations between minimum brain tissue 
concentration (Cmin) and Cmax in steady state (g). Population simula-
tion (n = 100) geometric means are shown as lines; the shaded areas 
represent the population geometric standard deviations. Detailed 
information about dosing regimens, study populations, and parame-
ters used for simulations is given in Tables S2.6.1, S2.7.1, S2.8.1, and 
S2.8.3 of the ESM. Peak-trough difference is not applicable for the 
transdermal therapeutic system (nicotine patch). cig. cigarettes
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Additionally, we present the first nicotine PBPK model 
that also includes and predicts nicotine concentration–time 
and heart rate profiles after e-cigarette use. In light of the 
ongoing discussions on the health risks of e-cigarettes and 
the fact that more than a quarter of high school students in 
the USA are current e-cigarette users with the figures still 
rising, our data might contribute to a better understanding 
of the persistent increase in youth e-cigarette use by serving 
as a basis for future studies on nicotine PK-based addiction 
models [4, 57].
Being widely used as a quantitative marker for exposures 
to nicotine and as a measure of compliance with treatments 
for smoking cessation [6, 18], cotinine was also included 
in the model. The glomerular filtration rate fraction of 0.06 
for cotinine, combined with the description of the fraction 
of cotinine dose excreted unchanged to urine, indicates 
high tubular reabsorption of cotinine in the kidney. Accu-
rate cotinine metabolite predictions after intravenous, oral 
(solutions, capsules), and transdermal administration could 
allow future investigations to perform reverse calculations to 
arrive at the amount of nicotine intake from cotinine plasma 
concentrations with this model. Because no cotinine metabo-
lite data after pulmonary and nicotine gum intake were avail-
able, cotinine formation could not be evaluated for these 
routes of administration. However, CYP2A6 expression in 
the lung was implemented according to the PK-Sim® expres-
sion database, to cover potential differences in cotinine for-
mation [58]. Variability in predictions for most intravenous, 
oral, and transdermal studies is better covered compared 
with pulmonary studies, where the variability observed is 
higher than predicted. This is as expected because variability 
in model predictions results from physiological differences, 
while the high variability after smoking results from dif-
ferences in puffing behavior (such as puff volumes) called 
smoking topography [59].
As a result, our findings support the assumption that dif-
ferences in smoking topography also lead to differences 
in nicotine plasma concentrations [46, 60]. The fact that 
the model is able to describe nicotine PK after the use of 
combustible cigarettes and e-cigarettes with the same pul-
monary administration model supports recent findings that 
Fig. 7  Predicted and observed 
heart rate profiles after intrave-
nous (iv) and pulmonary (com-
bustible cigarette [comb. cig.] 
and electronic cigarette [e-cig.]) 
administration. Population 
simulation (n = 100) geomet-
ric means are shown as lines; 
the shaded areas represent the 
predicted population geomet-
ric standard deviations (SDs). 
Observed data are shown as 
filled circles, if available ± SD. 
(i): selection of internal training 
dataset, (e): selection of external 
test dataset. References with 
numbers in parentheses link 
to a specific observed dataset 
described in the study table 
with detailed information about 
dosing regimens (Table S2.6.3 
of the ESM). m.d. multiple dose 
[27, 70, 80, 81]
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differences in plasma PK result from different smoking and 
vaping patterns, respectively [61].
Although transmucosal absorption was neglected dur-
ing the administration of nicotine gums, predictions for 
nicotine plasma profiles show very promising results. The 
future development of a physiological transmucosal PBPK 
model could help predict cotinine metabolite concentrations 
after the administration of nicotine gums. The expansion 
of our PBPK model with a two-compartment transdermal 
skin model led to better descriptions of nicotine and coti-
nine metabolite plasma profiles after transdermal absorp-
tion, compared with an existing transdermal nicotine PBPK 
model [53]. Thereby, it was possible to extrapolate patch 
parameter sets from the 30-mg single-dose Bannon et al. 
[62] study to 15-mg and 60-mg patches and to a multiple-
dose administration. This indicates that extrapolation from 
one dose to higher and lower doses as well as from single to 
multiple doses is possible with the implemented transder-
mal model. However, more research needs to be conducted 
to increase the mechanistic component of the transdermal 
model. As a result of the good predictive PK performance of 
the intravenous nicotine PBPK model, future studies could 
use the mechanistic model to de novo predict nicotine and 
cotinine plasma concentrations based on patch characteris-
tics and in vitro dissolution data.
The simulation study results of nicotine brain concen-
tration patterns show decisive differences: the lower dose 
nicotine gums (2 mg) yield lower brain concentrations of 
about half the magnitude (Cmax,brain) and extent (AUC brain) 
as the cigarette study arm does. Brain concentrations during 
nicotine patch application also do not reach the same mag-
nitude as the simulation with cigarettes does. In contrast, 
the use of 16 nicotine gums of 4 mg causes similar Cmax,brain 
and AUC brain values in brain concentrations. However, the 
fluctuation (peak-trough difference) stays lower, compared 
with smoking cigarettes. While the AUC brain of the nicotine 
patch trails behind the AUC brain of the cigarette study arm 
after 16 h, the AUC brain during the last 8 h is larger, com-
pared with inhalation.
The nicotine brain concentration data used for model 
building represent nicotine concentrations in the whole 
brain tissue and do not specifically show concentrations at 
the nicotine receptor site. Thus, brain concentration simu-
lations were also executed for brain tissue concentrations. 
To describe the brain tissue concentration profile included 
in the model development, the implementation of an influx 
and an efflux transporter in the BBB was necessary and is 
supported by the literature [21]. As data on nicotine brain 
tissue concentrations are scarce, only one brain kinetic 
profile was available to inform the model. Moreover, the 
brain tissue concentrations were determined only during 
a time span of 10 min after a single puff of combustible 
cigarettes [11]. Therefore, extrapolations to brain tissue 
simulations, especially of higher doses and longer time-
frames, have to be interpreted carefully.
The magnitude of increase in heart rate is a surrogate 
measure for general pharmacological actions of nico-
tine. Two PBPK/PD heart rate models from the literature 
included studies only after intravenous and transdermal 
administration of nicotine [52, 53]. In contrast, while our 
PD model was also built based on intravenous adminis-
tration data, it was expanded and evaluated with heart 
rate data from study participants consuming combusti-
ble cigarettes, e-cigarettes, and nicotine gums. Moreo-
ver, we included circadian rhythm for heart rate, as the 
heart rate undergoes marked fluctuations throughout the 
day [63]. We succeeded in incorporating acute tolerance 
development to the heart rate effect, which can not only 
be observed after the intake of nicotine but also after other 
substances, such as cocaine or ponesimod [20, 64]. Unfor-
tunately, no heart rate data measured during a whole day of 
nicotine administration were available. The longest study 
which is included in the PD model development lasted 
about 6 h. Hence, extrapolations beyond this time domain 
should be investigated carefully.
The positive chronotropic effect of nicotine probably 
results from several effects. First, nicotine stimulates epi-
nephrine and norepinephrine release by the activation of the 
ligand-gated cation channel nicotine acetylcholine receptors 
localized mainly on peripheral postganglionic sympathetic 
nerve endings and the adrenal medulla. Additionally, sympa-
thetic stimulation can occur through the activation of periph-
eral carotid body chemoreceptors [65–67]. Moreover, a close 
relationship between plasma concentrations of nicotine and 
the cardiovascular effects has been observed after acute 
exposure to nicotine [9, 65]. As a result, the PD effect was 
linked to the plasma concentrations. Linking the PD effect 
to concentrations of the heart or the brain compartment led 
to less precise predictions of heart rate changes.
Simulations of heart rate changes during the administra-
tion of four cigarettes, 16 cigarettes (1.4 mg each, smoked 
within 8 h), 16 nicotine gums (2 mg each), and a transder-
mal nicotine patch (21 mg in 24 h) have been performed 
(see Sect. 3.12 of the ESM). The results suggest a persistent 
increase in the baseline heart rate when smoking one ciga-
rette every 30 min (about 9 beats/min), which is supported 
by clinical studies [67]. Whereas only a slight increase of 
heart rate baseline can be observed when simulating the 
administration of cigarettes smoked 2 h apart, an increased 
baseline level holds true also for the administration of nico-
tine gums and the nicotine patch, albeit to a lower extent 
(about 6 beats/min and 4 beats/min, respectively). These 
differences are consistent with published work showing a 
decrease in heart rate when switching from smoking ciga-
rettes to the use of nicotine gums or patches [68, 69].
1132 L. Kovar et al.
5  Conclusions
A comprehensive whole-body parent–metabolite PBPK/
PD model of nicotine and cotinine has been built that 
can predict (1) nicotine and cotinine plasma concentra-
tion–time profiles after various routes of administration, 
(2) nicotine brain tissue concentrations, and (3) the posi-
tive chronotropic effect of nicotine. The physiologically 
based modeling approach integrated the available in vitro, 
in vivo, and in silico information on nicotine and could 
help enhance the understanding of dependence on com-
bustible cigarettes and e-cigarettes. The model was used 
to simulate and compare nicotine brain concentration pat-
terns during smoking and the application of NRTs. The 
model is thoroughly documented in the ESM, and the 
model files are publicly available in the OSP repository 
(https ://www.open-syste ms-pharm acolo gy.org). With that, 
the model can be used for the development of a detailed 
physiological transdermal and transmucosal nicotine 
model, contribute to a library of PBPK models for predic-
tions in special populations, and help with future inves-
tigations of nicotine pharmacokinetics and pharmacody-
namics, including the design of clinical trials and novel 
formulations to treat nicotine dependence.
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